Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Pocket Additional $13.4M as Underwriters Exercise Stock Options

NEW YORK, May 25 (GenomeWeb News) - Illumina yesterday said it stands to pocket an additional $13.4 million after the underwriters for its public stock offering exercised their option to buy a maximum of 525,000 additional shares for $25.50 apiece.

The company said that a total of 4.025 million shares were sold in the stock offering for a net gain of $96.2 million. As GenomeWeb News reported last week, Illumina expected to pocket net proceeds of about $83.6 million from the sale.

Goldman, Sachs & Co. and Merrill Lynch & Co. performed joint bookrunning and acted as co-lead managers of the offering, while Cowen and Company and Robert W. Baird & Co. acted only as co-lead managers.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.